JP MORGAN/CALL/ELI LILLY & CO/790/0.01/17.01.25 | Market Closed - Börse Stuttgart 03:39:48 27/06/2024 pm IST | ||
| 1.59 EUR | +6.71% |
|
| Current month | +43.27% | ||
| 1 month | +49.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 1.59 | +6.71% |
| 25/24/25 | 1.49 | +2.76% |
| 24/24/24 | 1.45 | 0.00% |
| 21/24/21 | 1.45 | -2.03% |
| 20/24/20 | 1.48 | -1.33% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 03:39 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK27V1 |
| ISIN | DE000JK27V19 |
| Date issued | 08/02/2024 |
| Strike | 790 $ |
| Maturity | 17/01/2025 (204 Days) |
| Parity | 100 : 1 |
| Emission price | 0.57 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.59 € |
|---|---|
| Lowest since issue | 0.62 € |
| Spread | 0.01 € |
| Spread % | 0.63% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Warrants
- Warrant
